Medtronic beats Boston Scientific in drug-eluting stent studies

Medtronic's Resolute drug-eluting stent beat out rival Boston Scientific's Taxus DES in late lumen loss after 8 months in a study that helps pave the way for Japanese regulatory approval for Resolute. In the language of drug-eluting stents, "late lumen loss" is the difference in millimeters between a stent just after the procedure and again after 6 to 9 months. Some loss in diameter of the stent is inevitable as tissue grows in, but there needs to be enough tissue suppression to that there is no further narrowing of a blood vessel. More here

Suggested Articles

The FDA has cleared its first fully disposable duodenoscope, following years of reports of infections being transmitted between patients.

OR-focused AI provider Caresyntax has garnered $45.6 million in new funding and picked up a data analytics firm to broaden its footprint.

A study of Foundation Medicine’s FoundationOne liquid biopsy test found it was able to predict the risk that a person’s breast cancer would return.